Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Wreckless Accusations
View:
Post by bball67 on Mar 10, 2022 1:47pm

Wreckless Accusations

Brought to you by King David. "This Company is committing fraud" and "insider trading". He concludes, from some misguided logic, a PR and the stock going down a penny and then up a penny. What the heck. Don't you need some kind of proof David to accuse the Company of such things? No you don't, you did it before. 

Maybe three months ago, David suggested that the three 2021 billionaire investors in Promis had excited their positions in Promis. They put in $27M and then they sold out their positions. This was totally false. This prompted Promis to have someone monitor the Stockhouse Bullboard. 

David will attack me personally as a response. He won't comment on his false allegations. Yes, I have been in the stock for 4+ years. Yes, I own almost 1.5M shares at .15 US. Yes, I have been disappointed in management, a lack of urgency and progress, Yes, I have incorrectly predicted faster progress and was way off. Yes, I made alot of money as a SRVP of a very successful public company. Yes, I have an eight figure net worth. Yes, my Promis investment is less that 2% of my net worth. Yes, I believe that this investment will be a grand slam home run. Did I forget anything David?
Comment by M101 on Mar 10, 2022 2:32pm
No one cares, but he's still the king if you need advice on matching drapes to carpets. As time goes on I'm getting less concerned about management. While I'd still like to see them change promotional strategies they do seem to be focused on what really matters given the cash on hand, for example not doing any promotion.
Comment by DavidKingCanada on Mar 10, 2022 4:23pm
M101 Hugs and Kisses because that's all your worth. Stop harassing Management and move tf on already before I teach you how to properly invest in Stocks. Bigballs = Small Testicles 
Comment by BottomBroker on Mar 11, 2022 1:17pm
King David is moron. The ignore button works wonders. 
Comment by M101 on Mar 11, 2022 2:15pm
King david also has an identity issue between trader and investor, while most traders have long departed. We keep seeing these very low volume periods interrupted by liquidation of earlier placement shares attractive now only to bottom feeders. Not a bad situation for many investors, but not optimal for royal clowns. Meanwhile, I was curious about AC Immune as it's been a fews years since ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities